Related Experiment Video
Updated: Aug 11, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Controlled-release carbidopa/levodopa in the treatment of Parkinsonism
Abstract:
Controlled release carbidopa/levodopa (CSR-1) was compared to standard carbidopa/levodopa in a double-blind, crossover study of 20 Parkinson's disease patients. The most consistent finding in a variety of clinical measurements was the superiority of standard carbidopa/levodopa to CSR-1. Increased dosages of CSR-1 resulted in reduced Parkinson symptoms, suggesting that a more potent controlled-release formulation might prove to be more efficacious than CSR-1.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology

